Paliperidone (Byannli) Receives EMA Approval in Europe, Expanding the Market for Schizophrenia Treatment
Approval Background
The EMA granted final approval for Byannli (paliperidone) as a maintenance treatment for schizophrenia and schizoaffective disorder on June 18, 2020. Its once-daily administration ensures stable blood concentrations, improving patient compliance.
Competitive Positioning
Paliperidone is considered to have easier dose adjustments and an improved side effect profile compared to risperidone. Its once-daily administration maintains efficacy for 24 hours, differentiating it from existing antipsychotics.
Reimbursement and Market Access Challenges
The reimbursement criteria vary across European countries, necessitating price negotiations. In particular, smaller countries may require additional cost-effectiveness data.
Market Size and Growth Prospects
The EMA approval enables sales in 27 EU member states, and the schizophrenia treatment market is estimated at approximately 3 billion euros annually. Paliperidone is expected to achieve a 5-7% annual revenue growth rate compared to existing drugs.
This approval allows Janssen to expand its European mental health treatment portfolio and secure stable cash flow. The new approval will also increase the demand for local sales and marketing personnel.
Source: EMA (ema)